Arquer Diagnostics (Arquer) is a private, UK-based diagnostics company focused on the development and commercialisation of non-invasive immunoassay diagnostic tests for cancer diagnosis and monitoring.
Arquer’s tests are based on minichromosome maintenance (MCM) protein, a marker for the presence of dividing cancer cells. This patent protected, intellectual property is licensed exclusively from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK.
Our initial focus is on the development of lab based tests for urological (prostate and bladder) cancers.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
For more details, please read our privacy statement